More than a thousand regenerative medicine clinical trials are underway globally, of which more than 40% are for cell therapies targeting cancer. Cell therapies have the potential to transform global healthcare by providing curative therapies for once incurable diseases. There are major challenges to the widespread adoption of cell therapies, primarily related to the high manufacturing costs of what is largely a manual process with complex logistics and supply chain.
Experts share their experiences and discuss emerging trends in the field to accelerate life-saving therapies from the bench to the bedside.
Dr. Wilson Bryan, director at the Office of Tissues and Advanced Therapies, FDA
Dr. Alison Moore, Chief Technology Officer at Allogene Therapeutics
Dr. Hari Pujar, operating partner at Flagship Pioneering
Dr. Greg Russotti, Chief Technology Officer at Century Therapeutics
Moderated by: Dr. Dolores Baksh, global solutions marketing leader for Cytiva’s cell therapy business